Format

Send to

Choose Destination
Psychiatr Clin North Am. 2015 Dec;38(4):843-60. doi: 10.1016/j.psc.2015.08.001. Epub 2015 Sep 11.

New Developments in Insomnia Medications of Relevance to Mental Health Disorders.

Author information

1
Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 27705, USA. Electronic address: andrew.krystal@duke.edu.

Abstract

Many insomnia medications with high specificity have become available recently. They provide a window into the clinical effects of modulating specific brain systems and establish a new guiding principal for conceptualizing insomnia medications: "mechanism matters." A new paradigm for insomnia therapy in which specific drugs are selected to target the specific type of sleep difficulty for each patient includes administering specific treatments for patients with insomnia comorbid with particular psychiatric disorders. This article reviews insomnia medications and discusses the implications for optimizing the treatment of insomnia occurring comorbid with psychiatric conditions.

KEYWORDS:

Comorbid psychiatric disorders; Doxepin; Eszopiclone; Insomnia; Personalization; Prazosin; Suvorexant

PMID:
26600112
PMCID:
PMC5972036
DOI:
10.1016/j.psc.2015.08.001
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center